PBM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Psyence Biomedical Ltd (PBM) is not a good buy for a beginner investor with a long-term strategy at this time. The company's financial performance is weak, with significant losses in net income and EPS. Additionally, the technical indicators suggest a bearish trend, and there are no strong positive catalysts or trading signals to support an immediate investment decision.
The MACD is above 0 but contracting, indicating weakening momentum. RSI is neutral at 38.224, and the stock is trading below key moving averages (SMA_200 > SMA_20 > SMA_5), signaling a bearish trend. The price is currently near its pivot level of 2.368, with resistance at 2.658 and support at 2.078.
The company has successfully exported a GMP-compliant psychedelic product for a Phase IIb clinical trial in Australia, which could lead to future growth opportunities if the trial is successful.
is also down by -1.23%.
In Q2 2026, the company reported no revenue growth (0% YoY), a significant drop in net income (-632.44% YoY), and a sharp decline in EPS (-142.23% YoY). Gross margin remained at 0%.
No analyst rating or price target data available.
